SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS

Embodiments of the disclosure relate to selectively substituted quinoline compounds of formula (I) that act as antagonists or inhibitors for Toll -like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis...

Full description

Saved in:
Bibliographic Details
Main Authors Lynn HAWKINS, Roch BOIVIN, Sally ISHIZAKA, Peter BERTINATO, Chikako OGAWA, Gregory BERGER, Shawn SCHILLER, Hans HANSEN, Atsushi ENDO, Sridhar NARAYAN, Robert T. YU, Matthew MACKEY
Format Patent
LanguageEnglish
Spanish
Published 29.03.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Embodiments of the disclosure relate to selectively substituted quinoline compounds of formula (I) that act as antagonists or inhibitors for Toll -like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis. Las modalidades de la descripción se refieren a compuestos de quinolina selectivamente sustituidos que actúan como antagonistas o inhibidores para receptores tipo Toll 7 y/u 8, y su uso en composiciones farmacéuticas efectivas para el tratamiento de lupus eritematoso sistémico (SLE) y nefritis lúpica.
Bibliography:Application Number: MX20160004629